Replies to post #17616 on Biotech Values

[DewDiligence]

>There are numerous examples of inaccurate, incomplete, and potentially misleading press releases that can be attributed to incompetence on behalf of the writer.<

My contention is that, in almost all of these cases, the companies in question are not worth owning.

If something in a PR is misleading, then it ought to be incumbent upon the company to issue a correction or clarification. When a correction or clarification does not follow, the inference one can draw is that:

1. The company does not care about its communications with investors; or
2. The misstatement was not accidental.

In either case, it’s a good sell signal, IMHO.